ArriVent BioPharma, Inc. AVBP Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s accounts payable?
- ArriVent BioPharma, Inc. (AVBP) reported accounts payable of $8.73M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s accounts payable changed year-over-year?
- ArriVent BioPharma, Inc.'s accounts payable increased by 100.0% year-over-year, from $4.36M to $8.73M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s accounts payable?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s accounts payable has grown at a 14.4% compound annual growth rate (CAGR), from $4.53M to $5.93M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.